Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isunakinra alone and with PD-(L)1 inhibitor in advanced solid tumors
NCT04121442Phase 2Completed
- Sponsor
- Buzzard Pharmaceuticals AB
- Start
- Sep 2020
- Primary completion
- Dec 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of isunakinra in solid tumor, sponsored by Buzzard Pharmaceuticals AB. Primary endpoints: Proportion of patients who experience DLTs at 49 days and Proportion of patients who experience decrease of IL-6 or hsCRP by >20% at 49 days. Started Sep 2020; status: completed.
02
Drugs
isunakinra
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04121442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04121442.